symproic
Generic: NALDEMEDINE TOSYLATE
symproic: developed by 2 companies · 1 FDA decision.
symproic evidence translation
What we can confirm
1 FDA record
What it means
More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
What is verified about symproic, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Treatment of opioid-induced constipation in adult patients with chronic non-cancer painTreatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI) Treatment of opioid-induced constipation in adult patients w… | Approved |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) Treatment of opioid-induced constipation (OIC) in adult pati… | Approved |
Frequently asked questions
Who is developing symproic?
symproic is being developed by BIODELIVERY SCIENCES INTERNATIONAL INC, COLLEGIUM PHARMACEUTICAL, INC.
What is symproic's latest FDA decision?
The most recent tracked FDA decision for symproic is Approval, dated March 23, 2017.